Top

Published in:

Open Access 01-02-2015 | Review

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer

Authors: Fabrice André, Javier Cortés

Published in: Breast Cancer Research and Treatment | Issue 1/2015

Abstract

Fibroblast growth factor receptor (FGFR) signaling is involved in multiple biological processes, including cell proliferation, survival, differentiation, migration, and apoptosis during embryonic development and adult tissue homeostasis. Given its role in the activation of critical signaling pathways, aberrant FGFR signaling has been implicated in multiple cancer types. A comprehensive search of PubMed and congress abstracts was conducted to identify reports on FGFR pathway components in breast cancer. In breast cancers, FGFR1 and FGFR4 gene amplification and single nucleotide polymorphisms in FGFR2 and FGFR4 have been detected. Commonly, these FGFR aberrations and gene amplifications lead to increased FGFR signaling and have been linked with poor prognosis and resistance to breast cancer treatments. Here, we review the role of FGFR signaling and the impact of FGFR genetic amplifications/aberrations on breast tumors. In addition, we summarize the most recent preclinical and clinical data on FGFR-targeted therapies in breast cancer. Finally, we highlight the ongoing clinical trials of the FGFR-targeted agents dovitinib, AZD4547, lucitanib, BGJ398, and JNJ-42756493, which are selected for patients with FGFR pathway-amplified breast cancer. Aberrant FGFR pathway amplification may drive some breast cancers. Inhibition of FGFR signaling is being explored in the clinic, and data from these trials may refine our ability to select patients who would best respond to these treatments.

Haugsten EM, Wiedlocha A, Olsnes S et al (2010) Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 8:1439–1452CrossRefPubMed

Johnson DE, Williams LT (1993) Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res 60:1–41CrossRefPubMed

Zhang H, Wu F, Tao YM et al (2009) Down-regulated expression of UNC5b related to hepatocellular carcinoma angiogenesis. Zhonghua Wai Ke Za Zhi 47:1569–1573PubMed

Itoh N, Ornitz DM (2011) Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 149:121–130CrossRefPubMedCentralPubMed

Adnane J, Gaudray P, Dionne CA et al (1991) BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 6:659–663PubMed

Jacquemier J, Adelaide J, Parc P et al (1994) Expression of the FGFR1 gene in human breast-carcinoma cells. Int J Cancer 59:373–378CrossRefPubMed

Courjal F, Cuny M, Simony-Lafontaine J et al (1997) Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res 57:4360–4367PubMed

Letessier A, Sircoulomb F, Ginestier C et al (2006) Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer 6:245CrossRefPubMedCentralPubMed

Elbauomy Elsheikh S, Green AR, Lambros MB et al (2007) FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 9:R23CrossRefPubMedCentralPubMed

10.

Andre F, Job B, Dessen P et al (2009) Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 15:441–451CrossRefPubMed

11.

Kadota M, Sato M, Duncan B et al (2009) Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA. Cancer Res 69:7357–7365CrossRefPubMedCentralPubMed

12.

Moelans CB, de Weger RA, Monsuur HN et al (2010) Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes. Mod Pathol 23:1029–1039CrossRefPubMed

13.

Turner N, Pearson A, Sharpe R et al (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70:2085–2094CrossRefPubMedCentralPubMed

14.

Penault-Llorca F, Bertucci F, Adelaide J et al (1995) Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer 61:170–176CrossRefPubMed

15.

Turner N, Lambros MB, Horlings HM et al (2010) Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29:2013–2023CrossRefPubMedCentralPubMed

16.

Jaakkola S, Salmikangas P, Nylund S et al (1993) Amplification of fgfr4 gene in human breast and gynecological cancers. Int J Cancer 54:378–382CrossRefPubMed

17.

Easton DF, Pooley KA, Dunning AM et al (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447:1087–1093CrossRefPubMedCentralPubMed

18.

Garcia-Closas M, Hall P, Nevanlinna H et al (2008) Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 4:e1000054CrossRefPubMedCentralPubMed

19.

Huijts PE, Vreeswijk MP, Kroeze-Jansema KH et al (2007) Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res 9:R78CrossRefPubMedCentralPubMed

20.

Hunter DJ, Kraft P, Jacobs KB et al (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39:870–874CrossRefPubMedCentralPubMed

21.

Meyer KB, Maia AT, O’Reilly M et al (2008) Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol 6:1098–1103CrossRef

22.

Stacey SN, Manolescu A, Sulem P et al (2008) Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 40:703–706CrossRefPubMed

23.

Bange J, Prechtl D, Cheburkin Y et al (2002) Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res 62:840–847PubMed

24.

Seitzer N, Mayr T, Streit S et al (2010) A single nucleotide change in the mouse genome accelerates breast cancer progression. Cancer Res 70:802–812CrossRefPubMed

25.

Sugiyama N, Varjosalo M, Meller P et al (2010) Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation. Cancer Res 70:7851–7861CrossRefPubMed

26.

Greenman C, Stephens P, Smith R et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 446:153–158CrossRefPubMedCentralPubMed

27.

Roidl A, Foo P, Wong W et al (2010) The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells. Oncogene 29:1543–1552CrossRefPubMed

28.

Katoh M (2010) Genetic alterations of FGF receptors: an emerging field in clinical cancer diagnostics and therapeutics. Expert Rev Anticancer Ther 10:1375–1379CrossRefPubMed

29.

Karlsson E, Waltersson MA, Bostner J et al (2011) High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1. Genes Chromosom Cancer 50:775–787CrossRefPubMed

30.

Garcia MJ, Pole JC, Chin SF et al (2005) A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes. Oncogene 24:5235–5245CrossRefPubMed

31.

Gelsi-Boyer V, Orsetti B, Cervera N et al (2005) Comprehensive profiling of 8p11-12 amplification in breast cancer. Mol Cancer Res 3:655–667CrossRefPubMed

32.

Yang ZQ, Streicher KL, Ray ME et al (2006) Multiple interacting oncogenes on the 8p11-p12 amplicon in human breast cancer. Cancer Res 66:11632–11643CrossRefPubMed

33.

Bernard-Pierrot I, Gruel N, Stransky N et al (2008) Characterization of the recurrent 8p11–12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer. Cancer Res 68:7165–7175CrossRefPubMed

34.

Cuny M, Kramar A, Courjal F et al (2000) Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cancer Res 60:1077–1083PubMed

35.

Sun S, Jiang Y, Zhang G et al (2012) Increased expression of fibroblastic growth factor receptor 2 is correlated with poor prognosis in patients with breast cancer. J Surg Oncol 105:773–779CrossRefPubMed

36.

Cerliani JP, Vanzulli SI, Pinero CP et al (2012) Associated expressions of FGFR-2 and FGFR-3: from mouse mammary gland physiology to human breast cancer. Breast Cancer Res Treat 133:997–1008CrossRefPubMed

37.

Liang J, Chen P, Hu Z et al (2008) Genetic variants in fibroblast growth factor receptor 2 (FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis 29:2341–2346CrossRefPubMed

38.

Peng S, Lu B, Ruan W et al (2011) Genetic polymorphisms and breast cancer risk: evidence from meta-analyses, pooled analyses, and genome-wide association studies. Breast Cancer Res Treat 127:309–324CrossRefPubMed

39.

Frullanti E, Berking C, Harbeck N et al (2011) Meta and pooled analyses of FGFR4 Gly388Arg polymorphism as a cancer prognostic factor. Eur J Cancer Prev 20:340–347CrossRefPubMed

40.

Meijer D, Sieuwerts AM, Look MP et al (2008) Fibroblast growth factor receptor 4 predicts failure on tamoxifen therapy in patients with recurrent breast cancer. Endocr Relat Cancer 15:101–111CrossRefPubMed

41.

Azuma K, Tsurutani J, Sakai K et al (2011) Switching addictions between HER2 and FGFR2 in HER2-positive breast tumor cells: FGFR2 as a potential target for salvage after lapatinib failure. Biochem Biophys Res Commun 407:219–224CrossRefPubMed

42.

Tomlinson DC, Knowles MA, Speirs V (2012) Mechanisms of FGFR3 actions in endocrine resistant breast cancer. Int J Cancer 130:2857–2866CrossRefPubMed

43.

Thussbas C, Nahrig J, Streit S et al (2006) FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J Clin Oncol 24:3747–3755CrossRefPubMed

44.

Harding TC, Long L, Palencia S (2013) Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci Transl Med 5:178ra39CrossRefPubMed

45.

Kabbarah O, Lerner L, Siddiquee Z et al (2009) Abstract #1348: fibroblast growth factor receptor-2 cancer models for biomarker discovery and therapeutic response prediction, in AACR Annual Meeting: Abstracts 1348

46.

Bai A, Meetze K, Vo NY et al (2010) GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling. Cancer Res 70:7630–7639CrossRefPubMed

47.

Reis-Filho JS, Simpson PT, Turner NC et al (2006) FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Clin Cancer Res 12:6652–6662CrossRefPubMed

48.

Koziczak M, Holbro T, Hynes NE (2004) Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 23:3501–3508CrossRefPubMed

49.

Ye T, Wei X, Yin T et al (2014) Inhibition of FGFR signaling by PD173074 improves antitumor immunity and impairs breast cancer metastasis. Breast Cancer Res Treat 143:435–446CrossRefPubMed

50.

Sharpe R, Pearson A, Herrera-Abreu MT et al (2011) FGFR signalling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res 17:5275–5286CrossRefPubMedCentralPubMed

51.

Bhide RS, Cai ZW, Zhang YZ et al (2006) Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 49:2143–2146CrossRefPubMed

52.

Shiang CY, Qi Y, Wang B et al (2010) Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Res Treat 123:747–755CrossRefPubMed

53.

Bhide RS, Lombardo LJ, Hunt JT et al (2010) The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther 9:369–378CrossRefPubMed

54.

Patel RR, Sengupta S, Kim HR et al (2010) Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Eur J Cancer 46:1537–1553CrossRefPubMedCentralPubMed

55.

Bello E, Colella G, Scarlato V et al (2011) E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res 71:1396–1405CrossRefPubMed

56.

Bello E, Taraboletti G, Colella G et al (2013) The tyrosine kinase inhibitor E-3810 combined with paclitaxel inhibits the growth of advanced-stage triple-negative breast cancer xenografts. Mol Cancer Ther 12:131–140CrossRefPubMed

57.

Lee SH, Lopes de Menezes D, Vora J et al (2005) In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models. Clin Cancer Res 11:3633–3641CrossRefPubMed

58.

Dey JH, Bianchi F, Voshol J et al (2010) Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis. Cancer Res 70:4151–4162CrossRefPubMed

59.

Issa A, Gill JW, Heideman MR et al (2013) Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. Breast Cancer Res 15:R8CrossRefPubMedCentralPubMed

60.

André F, Bachelot T, Campone M et al (2013) Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res 19:3693–3702CrossRefPubMed

61.

Patel K, Fattaey A, Burd A (2010) ACTB-1003: an oral kinase inhibitor targeting cancer mutations (FGFR), angiogenesis (VEGFR2, TEK), and induction of apoptosis (RSK and p70S6K). ASCO Meeting Abstracts 28:e13665

62.

O’Hare T, Shakespeare WC, Zhu X et al (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401–412CrossRefPubMedCentralPubMed

63.

Huang WS, Metcalf CA, Sundaramoorthi R et al (2010) Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-Abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 53:4701–4719CrossRefPubMed

64.

Zhou T, Commodore L, Huang WS et al (2011) Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance. Chem Biol Drug Des 77:1–11CrossRefPubMed

65.

Gozgit JM, Wong MJ, Moran L et al (2012) Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 11:690–699CrossRefPubMed

66.

Andre F, Neven P, Musolino A et al (2013) Dovitinib plus fulvestrant in postmenopausal endocrine resistant HER2-/HR + breast cancer: a phase II, randomized, placebo-controlled study. ASCO Meeting Abstracts 31:TPS651

67.

Gavine PR, Mooney L, Kilgour E et al (2012) AZD4547: an orally bioavailable, potent and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res 72:2045–2056CrossRefPubMed

68.

Smyth EC, Turner NC, Popat S et al (2013) FGFR: proof-of-concept study of AZD4547 in patients with FGFR1 or FGFR2 amplified tumours. ASCO Meeting Abstracts 31:TPS2626

69.

Soria J, De Braud FG, Cereda R et al (2011) First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors. ASCO Meeting Abstracts 29:TPS149

70.

Dienstmann R, Andre F, Soria J et al (2012) Significant antitumor activity of E-3810, a novel FGFR and VEGFR inhibitor, in patients with FGFR1 amplified breast cancer. Ann Oncol, ESMO Annual Meeting Abstracts 23:319O

71.

Sequist LV, Cassier P, Varga A et al (2014) Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. AACR Annual Meeting: Abstract CT326

72.

Dienstmann R, Bahleda R, Adamo B et al (2014) First in human study of JNJ-42756493, a potent pan fibroblast growth factor receptor (FGFR) inhibitor in patients with advanced solid tumors. AACR Annual Meeting: Abstract CT325

73.

Suzuki Y, Saeki T, Aogi K et al (2013) A multicenter phase II study of TSU-68, a novel oral multiple tyrosine kinase inhibitor, in patients with metastatic breast cancer progressing despite prior treatment with an anthracycline-containing regimen and taxane. Int J Clin Oncol 18:590–597CrossRefPubMed

74.

Toi M, Saeki T, Iwata H et al (2014) A multicenter phase II study of TSU-68, an oral multiple tyrosine kinase inhibitor, in combination with docetaxel in metastatic breast cancer patients with anthracycline resistance. Breast Cancer 21:20–27CrossRefPubMed

75.

Hilberg F, Roth GJ, Krssak M et al (2008) BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 68:4774–4782CrossRefPubMed

Title: Rationale for targeting fibroblast growth factor receptor signaling in breast cancer
Authors: Fabrice André
Javier Cortés
Publication date: 01-02-2015
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-015-3301-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials

Association between aspirin use and mortality in breast cancer patients: a meta-analysis of observational studies

Cost-effectiveness of prophylactic granulocyte colony-stimulating factor for febrile neutropenia in breast cancer patients receiving FEC-D

Contralateral breast cancer risk in relation to tumor morphology and age—in which patients is preoperative MRI justified?

Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer

Cancer stem cell and epithelial–mesenchymal transition markers predict worse outcome in metaplastic carcinoma of the breast

Keynote webinar | Spotlight on antibody–drug conjugates in cancer